Aqeel Mandviwala, MD
Pulmonary Disease · London, KYNPI 1326016460
Payments from drug & device makers
Across 513 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- GSK$1K
- Grifols USA, LLC$913
- Mylan Specialty L.p.$612
- Sanofi$487
- plus $3K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $2,221 |
| Boehringer Ingelheim | 90 | $1,840 |
| GSK | 89 | $1,464 |
| Grifols USA, LLC | 36 | $913 |
| Mylan Specialty L.p. | 30 | $612 |
| Sanofi | 24 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $410 |
| Pfizer | 22 | $349 |
| Harmony Biosciences LLC | 10 | $216 |
| Insmed, Inc. | 11 | $212 |
| Axsome Therapeutics, Inc. | 9 | $205 |
| Genentech USA, Inc. | 11 | $197 |
| Amgen | 6 | $196 |
| Pulmonx Corporation | 2 | $187 |
| Actelion Pharmaceuticals US, Inc. | 5 | $186 |
| Sunovion Pharmaceuticals Inc. | 11 | $169 |
| Grifols Shared Services North America, Inc. | 1 | $145 |
| Mallinckrodt Hospital Products Inc. | 3 | $126 |
| Intuitive Surgical | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $102 |
| Electromed, Inc. | 6 | $91 |
| Philips North America LLC | 5 | $86 |
| Verona Pharma, Inc. | 4 | $85 |
| Circassia Inc. | 4 | $70 |
| Viatris Specialty LLC | 3 | $57 |
| Shire North American Group Inc | 3 | $44 |
| Merck | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| AbbVie | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| CSL Behring | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$10,983 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in London
- Abdul SiddiquiLondon$16K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.